alexa Immunosupression |OMICS International| Chemotherapy: Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.


A patient immune response can have an important role in preventing the development of malignancy and immunotherapy has promise in treating neoplasia. However, patients with cancer, especially those with advanced disease, are known to be immunologically compromised, facilitating tumor progression and limiting the efficacy of immune intervention. This is called as Immunosupression and should be treated in order to develop resistance and avoid susceptibility to other diseases. Immunity in cancer patients is negatively regulated by a number of tumor induced cellular mechanisms, including regulatory T-cells (Tregs) and Myeloid-Derived Suppressor Cells (MDSCs). It is our hope that increasing our understanding of the mechanisms that hinder immune cell number
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on June, 2014